Kevin Cox's Biography

Kevin Cox, Chief Executive Officer, Imanova Limited

Kevin is CEO of Imanova Limited, a unique joint venture between the MRC and London’s three leading university colleges, King’s College London, Imperial College London and UCL. Established in 2011 with the acquisition of GSK’s renowned Clinical Imaging Centre, Imanova and its partners have world-leading expertise to drive research and innovation in imaging sciences, directly benefiting our understanding of disease and improving drug development for patient benefit.

Kevin’s broad experience includes establishing and leading innovative, high-growth businesses, working with the NHS and academia, and the design and implementation of innovative Public/Private partnerships. Additionally, Kevin is experienced in biopharmaceutical development – both clinical and non-clinical, laboratory diagnostics development and service provision, and the translation of new technology for clinical and commercial benefit.

Prior to Imanova, Kevin was Managing Director of GSTS Pathology, a unique joint venture between the NHS and the private sector established to lead the way in pathology modernisation. Before that Kevin was President of Avecia Biologics having served previously as Vice President of Avecia Biotechnology.

Separately, Kevin has held a number of public sector roles, namely Chair of UKTI’s Bio/Pharma Sector Advisory Committee (supporting trade and inward investment for Life Sciences in the UK), Chair of BioNow Advisory Committee (establishing a strong biomedical cluster in England’s North West), a member of the UK Life Sciences Marketing Strategy Board. He currently sits on the TSB’s advisory board for stratified medicine and is a non-executive director of the British Neuroscience Association (BNA) and has been elected to the Board of the BIA.

Kevin has a doctorate and a bachelor’s degree in Chemistry.